On the evening of February 27th, 65438, Ke Hua Bio disclosed important matters. Li Ming, director and general manager of Xi An Tianlong Technology Co., Ltd. and Suzhou Tianlong Biotechnology Co., Ltd. (hereinafter referred to as "Xi An Tianlong" and "Suzhou Tianlong" respectively, collectively referred to as "Tianlong Company"), made it clear to the listed companies that they could not cooperate with Ke Hua Bio-pre-audit accounting statements and follow-up audit work at present.
Behind the out-of-control of Tianlong Company is the huge difference between Ke Hua Bio and the counterparty on the confirmation of the purchase price of the remaining 38% equity of Tianlong Company. Ke Hua Bio-management and Tianlong Company completely "torn their faces" because Tianlong Company's performance broke out last year, and the two sides had great differences on the purchase price of the underlying residual equity.
Brief introduction of Ke Hua's biology
Ke Hua Bioengineering Co., Ltd. was established in 198 1, which is the largest industrial base of medical diagnostic products in China. Ke Hua Bio is the first professional diagnostic product company listed on Shenzhen Stock Exchange in China, which integrates product research and development, production and sales, and has a complete industrial chain in the field of medical diagnosis. The company's main business covers in vitro diagnostic reagents, medical inspection instruments, inspection information technology and vacuum blood collection system.
From June 5438 to February 2020, the list of the top 500 listed manufacturing companies in China in 2020 was released, and Ke Hua Bio ranked 450th.